ArticleBMC veterinary research2025
Immunization of pigs with Actinobacillus pleuropneumonia live attenuated (gene-deleted) vaccine HB04M intramuscularly or intranasally exhibits remarkably rapid protection against heterologous strain challenge.
Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- WH01-3A: a DIVA-compliant, ApxIA, ApxIIA, and ApxIIIA expressing Actinobacillus pleuropneumoniae live attenuated vaccine strain that protects mice and pigs against homologous and heterologous serovars.Veterinary research · 2026Article
- Timing of florfenicol administration determines the protective efficacy of an Actinobacillus pleuropneumoniae live attenuated vaccine in pigs.BMC veterinary research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Actinobacillus pleuropneumonia (APP) is the etiological agent of porcine pleuropneumonia, characterized by acute hemorrhagic fibrinous pleuropneumonia and chronic fibrinous necrotizing pleuropneumonia. The acute manifestation of APP is marked by a high fatality rate, leading to substantial economic repercussions to the global swine industry. Current vaccination strategies against APP primarily include bacterin vaccines, subunit vaccines, and live attenuated vaccines. However, their immediate protective efficacy after immunization, particularly for emergency scenarios, remains poorly characterized. In this study, pigs were immunized with APP live attenuated (gene-deleted) vaccine HB04M (serovar 7) via intramuscular or intranasal route at 3 and 7 days prior to challenge with a virulent heterologous serotype strain (serovar 5) at a lethal dose. The findings revealed that pigs receiving intramuscular vaccination 7 days pre-challenge demonstrated a significantly effective immunological defense, achieving a 100% survival rate with minimal lung injury. Intramuscular vaccination 3 days and intranasal vaccination 7 days pre-challenge both exhibited 80% protection, while intranasal vaccination 3 days pre-challenge offered only 60% protection against the challenge. The immediate protection observed 3 days post-immunization was correlated with the rapid vaccine-induced IFN-γ response, while protection at 7 days post-immunization was enhanced by the synergistic effects of HB04M-induced antibodies and IFN-γ. Overall, HB04M demonstrated significant protection against a lethal dose of the heterologous strain as early as 3 days post-immunization, with intramuscular vaccination delivering nearly complete protection by 7 days post-immunization. These findings suggest that HB04M could serve as an effective emergency vaccination strategy during APP outbreaks in pig farms, providing timely protection to mitigate morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.